For Q1 of the 2026 fiscal year, revenue was 163.3 billion yen, a substantial year\u2011over\u2011year increase; full-year guidance is around 700.0 billion yen, with progress at 23.3%. Major drivers are higher overseas subsidiaries, exports, and the impact of the ViiV Healthcare equity-method affiliate. Operating income was 66.9 billion yen year over year, quarterly net income was 97.7 billion yen. The Barber Edarabon business succession led to significant increases in tangible and intangible assets.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4507","jir_company_name":"Shionogi & Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-08-03","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/08\/4507-20260803-02.pdf","jir_short_summary":"For Q1 of the 2026 fiscal year, revenue was 163.3 billion yen, a substantial year\u2011over\u2011year increase; full-year guidance is around 700.0 billion yen, with progress at 23.3%. Major drivers are higher overseas subsidiaries, exports, and the impact of the ViiV Healthcare equity-method affiliate. Operating income was 66.9 billion yen year over year, quarterly net income was 97.7 billion yen. The Barber Edarabon business succession led to significant increases in tangible and intangible assets.","jir_summary":"### Overview of Results\nConsolidated revenue for Q1 reached 163.3 billion yen, marking a substantial increase year over year, driven by stronger contributions from domestic and international pharmaceutical businesses and royalty income. Operating income was 66.9 billion yen, and quarterly net income was 97.7 billion yen. The effects of equity-method investments in ViiV Healthcare and the structural impact of the Edarabon business succession were primary factors. The full-year guidance is 700.0 billion yen, with progress at 23.3%.\n\n### Outlook and Focus Areas\nThe Edarabon business succession has led to large increases in intangible assets and goodwill, influencing the financial structure. It remains to be seen whether overseas sales growth will continue and how the JT Pharmaceutical business and Torii Pharmaceutical consolidation will affect future cost structure. Also to monitor are progress toward the full-year forecast and currency effects.","jir_financial_highlights":"Revenue: 1,633 (\u5bfe\u524d\u671f\u5897\u6e1b\u984d 635)\nOperating Income: 669 (\u5bfe\u524d\u671f\u5897\u6e1b\u984d 318)\nQuarterly Net Income: 977 (\u5bfe\u524d\u671f\u5897\u6e1b\u984d 584)\nFull-Year Revenue Guidance: 7,000 (\u5bfe\u4e88\u60f3\u9032\u6357\u7387 23.3\uff05)\nGoodwill\/Intangible assets increase due to Edarabon business succession: Goodwill 349, Intangible assets 3,741 (\u5bfe\u524d\u5e74\u5ea6\u672b)","jir_category":"","jir_hashtags":"#Shionogi, #IR, #JapanStocks","jir_key_figures":"Revenue: 1,633 (\u5bfe\u524d\u671f\u5897\u6e1b\u984d 635, \u5bfe\u524d\u671f\u5897\u6e1b\u7387 63.7%)\nOperating Income: 669 (\u5bfe\u524d\u671f\u5897\u6e1b\u984d 318, \u5897\u6e1b\u7387 90.6%)\nQuarterly Net Income: 977 (\u5bfe\u524d\u671f\u5897\u6e1b\u984d 584, \u5897\u6e1b\u7387 148.3%)","jir_meta_title":"Shionogi Q1 20XX Results | Revenue 163.3 billion yen, Operating Income 66.9 billion yen","jir_meta_description":"Summary of Shionogi's Q1 financial results supplement released on August 3, 2026. Covers trends in revenue, operating income, quarterly net income, full-year guidance and progress, and the impact of the Edarabon business succession.","jir_og_title":"Shionogi Q1 Results Highlights","jir_og_description":"Highlights of Shionogi's Q1 results: Revenue 163.3 billion yen, Operating Income 66.9 billion yen, full-year guidance 7,000 billion yen, etc.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":6919,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-93449","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n